Weeks after criticising the group’s big pharma partner, John Houston is on his way out.

The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.

Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.

But camizestrant’s use could depend on uptake of monitoring – for now.

Any hopes of differentiation could come down to side effects.

Crunch time approaches for UroGen.

Meanwhile, Pfizer reckons it's found the right dose for its KAT6.

Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.

A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.